Multiple Myeloma and Plasma Cell Neoplasm — Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Citation(s)
A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma